Gross profit*
19
0
0
Texte intégral
(2) Profit & Loss: Key Figures (in million Euro) Q1 '10. Sales. 662. 664. +0.3% (+0.7%). Gross profit*. 208. 229. +10.1%. 31.4%. 34.5%. -41. -37. -9.8%. -144. -136. -5.6%. 21.8%. 20.5%. 5. -1. 55. 77. 8.3%. 11.6%. 28. 53. 4.2%. 8.0%. as a % of sales. R&D* SG&A* as a % of sales. Other operating items* Recurring EBITDA* as a % of sales. Recurring EBIT* as a % of sales. 40.0%. +89.3%. * Before restructuring charges and non-recurring items. Slight revenue increase due to recovery graphic industry and revenue performance of HealthCare EBIT almost doubled versus Q1’09 2. WorldReginfo - 9b6fa673-0150-40ed-a252-801accb22682. % change (excl. curr.). Q1 '09.
(3) Net Financial Debt (in million Euro). 715. 852 721. 703. 737. 723. 673. 661 569 500 445. 434. Q1 '07 Q2 '07 Q3 '07 Q4 '07 Q1 '08 Q2 '08 Q3'08 Q4'08 Q1'09 Q2'09 Q3'09 Q4'09 Q1'10. 3. WorldReginfo - 9b6fa673-0150-40ed-a252-801accb22682. 809.
(4) Working Capital: Key Figures (in million Euro/days) Inventories. Trade Receivables*. 800. 800. 800 763 705 717. 700. 740 747. 765. 692. 700. 720 726 681. 600 578. 605607. 633 575. 591 543. 500. 639. 600. 600. 577 539. 514. 500. 400 300 121 122 117 97 101. 200. 103 108. 105 100 105 99 97 93. 469 473 400. 400. 300. 300 328 321. 200. 87 79. 100. 100. 0. 500. 521 532. 483. 85. 80. 75 78. 69 70. 64 58. 100. 275274. 226 212. 187 191. 206 211. 56 55 42. Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 '07 '07 '07 '07 '08 '08 '08 '08 '09 '09 '09 '09 '10. 46 46 43 43. 39 38. 34 36. 40 41. Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 '07 '07 '07 '07 '08 '08 '08 '08 '09 '09 '09 '09 '10. * Trade receivables minus deferred revenue and advanced payments from customers. Working capital decreased by 155 million Euro versus Q1‘09 4. 257 253. 0. 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 '07 '07 '07 '07 '08 '08 '08 '08 '09 '09 '09 '09 '10. 249. 200. 86 84. WorldReginfo - 9b6fa673-0150-40ed-a252-801accb22682. 700. Trade Payables.
(5) Main Group Drivers behind Key Figures. 5. WorldReginfo - 9b6fa673-0150-40ed-a252-801accb22682. Q1 2010 • Slight revenue increase due to recovery graphic industry and revenue performance of HealthCare • Gross profit improved significantly as a result of the efficiency improvement programs and the increased use of the manufacturing capacity • EBIT almost doubled versus Q1’09.
(6) Profit & Loss: Key Figures (in million Euro). Restructuring and non-recurring Operating result Non-operating result Profit before taxes Taxes and minority interest Net result. 6. Q1 '10. 28. 53. +89.3%. 9. -2. +122.2%. 37. 51. +37.8%. -30. -23. -23.3%. 7. 28. +300.0%. -16. -10. -37.5%. -9. 18. +300.0%. % change. WorldReginfo - 9b6fa673-0150-40ed-a252-801accb22682. Recurring EBIT. Q1 '09.
(7) WorldReginfo - 9b6fa673-0150-40ed-a252-801accb22682. Agfa Graphics.
(8) Graphics: Key Figures (in million Euro) Sales. Q1 '10 % change (excl. curr.). 315. 345. +9.5% (+9.7%). 84. 105. +25.0%. 26.7%. 30.4%. R&D*. -12. -10. -16.7%. SG&A*. -69. -70. +1.4%. 21.9%. 20.3%. -2. 0. Recurring EBITDA*. 13.5. 35.1. as a % of sales. 4.3%. 10.2%. Recurring EBIT*. 1.2. 24.6. as a % of sales. 0.4%. 7.1%. Gross profit* as a % of sales. as a % of sales. Other operating items*. +160.0%. N.R.. * Before restructuring charges and non-recurring items.. Mainly in US and emerging countries, the graphic markets are recovering from the economic crisis Gross profit and EBIT improved significantly due to increased use of manufacturing capacity and the continuous improvement programs 8. WorldReginfo - 9b6fa673-0150-40ed-a252-801accb22682. Q1 '09.
(9) Graphics: YTD Sales per Business Segment YTD 2010 100% = 345 million Euro. Analog Prepress 22%. Digital Prepress 65%. 9. WorldReginfo - 9b6fa673-0150-40ed-a252-801accb22682. Inkjet, Software, Service 13%.
(10) Graphics: Main Drivers behind Key Figures. 10. WorldReginfo - 9b6fa673-0150-40ed-a252-801accb22682. Q1 2010 • Mainly in the US and in the emerging countries, the graphic markets are recovering from the economic crisis • Prepress as well as Inkjet contributed to topline growth • Both Gross profit (margin) and EBIT (margin) improved due to increased use of manufacturing facilities and continuous improvement programs.
(11) WorldReginfo - 9b6fa673-0150-40ed-a252-801accb22682. Agfa HealthCare.
(12) HealthCare: Key Figures (in million Euro) Q1 '10 % change (excl. curr.). Sales. 291. 276. -5.2% (-4.2%). Gross profit*. 112. 112. 0.0%. 38.5%. 40.6%. R&D*. -27. -24. -11.1%. SG&A*. -67. -60. -10.4%. 23.0%. 21.7%. 8. 0. Recurring EBITDA*. 39.0. 39.8. as a % of sales. 13.4%. 14.4%. 25.5. 27.6. as a % of sales. as a % of sales. Other operating items*. Recurring EBIT* as a % of sales. 8.8% * Before restructuring charges and non-recurring items.. +2.1%. +8.2%. 10.0%. Imaging revenue decreased due to seasonal effects and ongoing market decline; IT sales remained stable Gross profit as well as EBIT increased due to improved service efficiency and increased use of manufacturing capacity 12. WorldReginfo - 9b6fa673-0150-40ed-a252-801accb22682. Q1 '09.
(13) HealthCare: YTD Sales per Business Segment YTD 2010 100% = 276 million Euro Hardcopy 29%. CR/Modalities 17%. HIS/CIS 11%. Imaging IT* 28%. HealthCare IT = 39%. * Includes Radiology and Cardiology IT 13. WorldReginfo - 9b6fa673-0150-40ed-a252-801accb22682. Classic Radiology 15%.
(14) HealthCare: Main Drivers behind Key Figures Q1 2010. 14. WorldReginfo - 9b6fa673-0150-40ed-a252-801accb22682. • Imaging revenue decreased due to seasonal effects and ongoing market decline; IT sales remained stable • Gross profit increased due to improved service efficiency and increased use of manufacturing capacity • EBIT margin improved to 10% of revenue.
(15) WorldReginfo - 9b6fa673-0150-40ed-a252-801accb22682. Agfa Specialty Products.
(16) Specialty Products: Key Figures (in million Euro) Q1 '10 % change (excl. curr.). Sales. 56. 43. -23.2% (-22.5%). Gross profit*. 11. 12. +9.1%. 19.6%. 27.9%. R&D*. -2. -3. +50.0%. SG&A*. -7. -7. 0.0%. 12.5%. 16.3%. 1. 0. Recurring EBITDA*. 3.5. 3.3. as a % of sales. 6.3%. 7.7%. 2.4. 2.3. as a % of sales 4.3% * Before restructuring charges and non-recurring items.. 5.4%. as a % of sales. as a % of sales. Other operating items*. Recurring EBIT*. 16. -5.7%. -4.2%. WorldReginfo - 9b6fa673-0150-40ed-a252-801accb22682. Q1 '09.
(17) Q1 2010 • Revenue decreased due to strong effect of shift of part of the film business to Agfa Graphics and market driven decline for some of the classic film products • Revenue increase for PCB film due to recovery of the electronics industry • Gross profit margin significantly improved due to increased use of manufacturing capacity • EBIT margin slightly improved. 17. WorldReginfo - 9b6fa673-0150-40ed-a252-801accb22682. Specialty Products: Main Drivers behind Key Figures.
(18) Outlook. 18. WorldReginfo - 9b6fa673-0150-40ed-a252-801accb22682. • The Agfa-Gevaert Group confirms the outlook included in the full year 2009 press release, published on March 31, 2010..
(19) WorldReginfo - 9b6fa673-0150-40ed-a252-801accb22682. Questions & Answers.
(20)
Documents relatifs
Our results show that climate change affects mean annual revenue, although the varia- tion between various GHG emission scenarios is low (lines 1, 6 and 7).. This is
aip, anterior insular point; als, anterior limiting sulcus; ap, insular apex; asg, accessory short insular gyrus; fs, falciform sulcus; ics, insular central sulcus;
By applying a two-stage model, estimating market fare volatility and posted prices in the first stage and revenue in the second, we find evidence that price sensitive consumers
Therefore, the results for our research question 1, “Which prod- uct-related services increase share of revenue, when directly invoiced?”, indicate that manufacturing companies,
OPERATIONS BY BUSINESS Strategy & Transformation consulting services 7% of Group revenues, grouped under Capgemini Invent, recorded sustained growth of 9.6% at constant exchange
Capgemini has taken advantage of its excellent performance in North America, where its revenue grew 11.7% on a like-for-like basis and 33.8% at current Group structure and
HotelInvest: First-quarter revenue up 4.8% like-for-like at €1,055 million At end-March 2015, HotelInvest had a portfolio of 1,350 hotels, of which 86% in Europe France, NCEE
In order to compare different types of relationship for a two-echelon supply chain and to identify which one generates the greatest profit for the network and for each partner,
